Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AYTU NYSEARCA:DBV OTCMKTS:IMUC NYSEAMERICAN:PHGE On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAYTUAytu BioPharma$2.15-1.8%$2.39$1.65▼$3.07$23.51M0.2440,260 shs14,399 shsDBVInvesco DB G10 Currency Harvest Fund$25.41$25.41$24.25▼$28.40$25.41M0.2327,852 shsN/AIMUCEOM Pharmaceutical$0.19-11.2%$0.14$0.04▼$0.34$27.07M-0.0519,086 shs1,056 shsPHGEBiomX$0.54-24.2%$1.32$0.36▼$14.71$7.90M1.1817.73 million shs13.02 million shsMissed the SpaceX IPO? Buy These 7 Stocks InsteadThe space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAYTUAytu BioPharma-2.23%+3.30%-4.78%-13.78%+13.47%DBVInvesco DB G10 Currency Harvest Fund0.00%0.00%0.00%0.00%0.00%IMUCEOM Pharmaceutical+0.05%-3.71%+114.47%+47.57%+85.62%PHGEBiomX+10.63%-15.60%+10.08%-88.57%-91.53%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAYTUAytu BioPharma$2.15-1.8%$2.39$1.65▼$3.07$23.51M0.2440,260 shs14,399 shsDBVInvesco DB G10 Currency Harvest Fund$25.41$25.41$24.25▼$28.40$25.41M0.2327,852 shsN/AIMUCEOM Pharmaceutical$0.19-11.2%$0.14$0.04▼$0.34$27.07M-0.0519,086 shs1,056 shsPHGEBiomX$0.54-24.2%$1.32$0.36▼$14.71$7.90M1.1817.73 million shs13.02 million shsMissed the SpaceX IPO? Buy These 7 Stocks InsteadThe space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAYTUAytu BioPharma-2.23%+3.30%-4.78%-13.78%+13.47%DBVInvesco DB G10 Currency Harvest Fund0.00%0.00%0.00%0.00%0.00%IMUCEOM Pharmaceutical+0.05%-3.71%+114.47%+47.57%+85.62%PHGEBiomX+10.63%-15.60%+10.08%-88.57%-91.53%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAYTUAytu BioPharma 2.40Hold$9.83357.36% UpsideDBVInvesco DB G10 Currency Harvest Fund 0.00N/AN/AN/AIMUCEOM Pharmaceutical 0.00N/AN/AN/APHGEBiomX 2.00Hold$26.004,748.94% UpsideCurrent Analyst Ratings BreakdownLatest PHGE, AYTU, DBV, and IMUC Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/11/2026AYTUAytu BioPharma Ascendiant Capital MarketsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$14.00 ➝ $14.505/11/2026AYTUAytu BioPharma Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong Sell ➝ Hold4/8/2026AYTUAytu BioPharma Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)3/31/2026AYTUAytu BioPharma Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeHold ➝ Strong Sell(Data available from 6/12/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAYTUAytu BioPharma$66.38M0.35$0.37 per share5.83$2.11 per share1.02DBVInvesco DB G10 Currency Harvest FundN/AN/AN/AN/AN/AN/AIMUCEOM PharmaceuticalN/AN/AN/AN/AN/AN/APHGEBiomXN/AN/AN/AN/A($12.50) per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAYTUAytu BioPharma-$13.56M-$4.58N/A8.60N/A-60.17%-69.93%-13.25%N/ADBVInvesco DB G10 Currency Harvest FundN/AN/AN/AN/AN/AN/AN/AN/AN/AIMUCEOM Pharmaceutical-$1.92MN/AN/AN/AN/AN/AN/AN/AN/APHGEBiomX-$36.20M-$3.21N/AN/AN/AN/A-2,923.50%-89.14%8/12/2026 (Estimated)Latest PHGE, AYTU, DBV, and IMUC EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/20/2026Q1 2026PHGEBiomXN/A$7.38N/A$7.38N/AN/A5/13/2026Q3 2026AYTUAytu BioPharma-$0.4433-$0.53-$0.0867-$0.53$12.05 million$12.41 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthAYTUAytu BioPharmaN/AN/AN/AN/AN/ADBVInvesco DB G10 Currency Harvest FundN/AN/AN/AN/AN/AIMUCEOM PharmaceuticalN/AN/AN/AN/AN/APHGEBiomXN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAYTUAytu BioPharma0.271.121.00DBVInvesco DB G10 Currency Harvest FundN/AN/AN/AIMUCEOM PharmaceuticalN/AN/AN/APHGEBiomXN/A1.241.24Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAYTUAytu BioPharma33.49%DBVInvesco DB G10 Currency Harvest Fund85.24%IMUCEOM PharmaceuticalN/APHGEBiomX40.57%Insider OwnershipCompanyInsider OwnershipAYTUAytu BioPharma4.90%DBVInvesco DB G10 Currency Harvest FundN/AIMUCEOM Pharmaceutical3.28%PHGEBiomX21.80%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAYTUAytu BioPharma16010.73 million10.21 millionNot OptionableDBVInvesco DB G10 Currency Harvest Fund801.00 millionN/ANot OptionableIMUCEOM Pharmaceutical3126.50 million122.35 millionNot OptionablePHGEBiomX12011.16 million8.73 millionN/APHGE, AYTU, DBV, and IMUC HeadlinesRecent News About These CompaniesBiomX Announces NYSE American Acceptance of Plan to Regain ComplianceJune 12 at 9:00 AM | globenewswire.comBiomX Inc. (NYSEAMERICAN:PHGE) Short Interest UpdateJune 12 at 3:51 AM | americanbankingnews.comBiomX: Zorronet’s AI Security Experts Provide In-Depth Review on Why Security AI Must Move Beyond Detection to Understanding in High-Stakes Global EventsJune 11 at 2:14 PM | markets.businessinsider.comBiomX Inc. Publishes Review on the Future of AI in Security Industry by Zorronet CEO Idan WassermanJune 11 at 9:31 AM | quiverquant.comQBiomX: Zorronet's AI Security Experts Provide In-Depth Review on Why Security AI Must Move Beyond Detection to Understanding in High-Stakes Global EventsJune 11 at 9:03 AM | globenewswire.comBiomX Issues Restricted Shares Under Mandragola Credit FacilityJune 5, 2026 | tipranks.comBiomX Inc. Appoints Prof. Gabby Sarusi as Strategic Advisor to Enhance Defense and Security CapabilitiesJune 2, 2026 | quiverquant.comQAnother Prominent Defense Technology Leader Joins BiomX: Prof. Gabby Sarusi, Former VP and Chief Scientist at ElbitJune 2, 2026 | globenewswire.comZorronet Brings Autonomous C5ISR to Hardened Sites Without Public Cloud DependenceJune 1, 2026 | globenewswire.comBiomX Inc. Appoints Roy Timor-Rousso as Chief Business Officer to Enhance Defense and Security LeadershipMay 27, 2026 | quiverquant.comQBiomX Appoints IDF Colonel (res.) Roy Timor-Rousso as Chief Business Officer to Strengthen Defense & Security OperationsMay 27, 2026 | globenewswire.comBiomX Delays Quarterly Report Amid Strategic ShiftMay 15, 2026 | tipranks.comBiomX Reinvents Itself as Diversified Defense Technology PlatformMay 15, 2026 | theglobeandmail.comBiomX’s Zorronet Puts Full AI Command-and-Control in the Palm of Your HandMay 6, 2026 | markets.businessinsider.comBiomX's Zorronet Puts Full AI Command-and-Control in the Palm of Your HandMay 6, 2026 | globenewswire.comZorronet Delivers 98% Success in Israel Railways Pilot, Awarded Framework Supply Agreement for AI-Powered Detection SystemsApril 16, 2026 | globenewswire.comBiomX Insider Trading Activity | AMEX:PHGE | BenzingaApril 13, 2026 | benzinga.comBiomX Inc. Acquires Controlling Interest in DFSL to Enhance Defense and Security CapabilitiesApril 13, 2026 | quiverquant.comQBiomX Accelerates Defense Technology Buildout with DFSL AcquisitionApril 13, 2026 | globenewswire.comBiomX Stockholders Approve 2026 Equity Incentive PlanApril 10, 2026 | tipranks.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimePHGE, AYTU, DBV, and IMUC Company DescriptionsAytu BioPharma NASDAQ:AYTU$2.15 -0.04 (-1.83%) Closing price 04:00 PM EasternExtended Trading$2.21 +0.06 (+2.79%) As of 06:29 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Aytu Biopharma, Inc. is a specialty pharmaceutical company, which engages in identifying, acquiring, and commercializing novel products. It operates through the Rx and Consumer Health segments. The RX segment consists of various prescription pharmaceutical products sold through third parties. The Consumer Health segment includes various consumer health products sold directly to consumers. Its products include Adzenys ER, Adzenys XR-ODT, Cotempla XR-ODT, Karbinal ER, Poly-Vi-Flor, Tri-Vi-Flor, Generic Tussionex, Tuzistra XR, and ZolpiMist. The company was founded on August 9, 2002 and is headquartered in Englewood, CO.Invesco DB G10 Currency Harvest Fund NYSEARCA:DBV$25.41 0.00 (0.00%) As of 03/10/2023PowerShares DB G10 Currency Harvest Fund (the Fund) is an index tracking fund and does not utilize any trading system, whether discretionary, systematic or otherwise. The Fund offers common units of beneficial interest (the Shares) only to certain eligible financial institutions (the Authorized Participants) in one or more blocks of 200,000 Shares, called a Basket. The Index is designed to reflect the return from investing on a 2:1 leveraged basis in long currency futures positions for certain currencies associated with relatively high yielding interest rates and in short currency futures positions for certain currencies associated with relatively low yielding interest rates. DB Commodity Services LLC serves as the managing owner, commodity pool operator and commodity trading advisor of the Fund.EOM Pharmaceutical OTCMKTS:IMUC$0.19 -0.02 (-11.17%) As of 02:19 PM EasternImmunocellular Therapeutics, Ltd., a clinical-stage pharmaceutical company, focuses on the development of therapeutics and delivery technologies for the treatment of inflammatory conditions and ocular diseases. Its lead clinical asset is EOM613 solution, a peptide nucleic-acid solution with anti-inflammatory and pro-inflammatory effects on cytokines and chemokines for the treatment of cancer cachexia and rheumatoid arthritis. The company also develops EOM 147, an investigational, broad-spectrum aminosterol with an intracellular mechanism for the treatment of chronic and debilitating retinal diseases. Immunocellular Therapeutics, Ltd. was founded in 2020 and is headquartered in Montvale, New Jersey.BiomX NYSEAMERICAN:PHGE$0.54 -0.17 (-24.24%) As of 04:10 PM EasternBiomX Inc., a clinical-stage microbiome company, develops products using natural and engineered phage technologies designed to target and kill specific harmful bacteria. It targets bacteria that affect the appearance of skin, as well as chronic diseases, such as inflammatory bowel diseases (IBD), primary sclerosing cholangitis (PSC), cystic fibrosis (CF), atopic dermatitis, and colorectal cancer (CRC). It is developing BX004, a phage therapy for CF patients with chronic Pseudomonas aeruginosa respiratory infections that is in Phase 1b/2a clinical trials. The company's pipeline products also include BX005, a topical phage cocktail, which is in Phase 1/2 clinical study that targets Staphylococcus aureus (S. aureus), a bacteria associated with the manifestation of the disease. In addition, the company engages in the provision of colorectal cancer program that utilizes engineered phage with various payloads, which are administered intravenously to target Fusobacterium nucleatum bacteria residing within the tumor microenvironment. BiomX Inc. was founded in 2015 and is headquartered in Ness Ziona, Israel. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas SpaceX Rings the Bell and Shatters Every Record Adobe Stock Just Got Cheaper—Is Wall Street Missing the Story? ERock IPO: A $1.3B Power Play Solution Boeing’s Unseen Rebound: Why the Headlines Are Wrong Why Oracle's 10% Drop May Be Telling the Wrong Story Spotify's "North Star" Outlook Was Music to Investors Ears DraftKings Hits the Jackpot With Super App Pivot Cracker Barrel Surges 23% as Earnings Beat Signals Turnaround Progress Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
